Calcitriol

Calcitriol

SCHEMBL3329859

C=C1/C(=C\C=C2/CCC[C@]3(C)[C@@H]([C@H](C)CCCC(C)(C)O)CC[C@@H]23)C[C@@H](O)C[C@@H]1O.[PbH2]

nearest known ligand 0.98

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

VDR

The experimentally established mechanism targets of Calcitriol. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
VDR known ✓ P11473 10/20 0.98
MAPT P10636 3/20 0.98
ADORA3 P0DMS8 2/20 0.98
SLC6A2 P23975 2/20 0.98
AGTR1 P30556 2/20 0.98
SMN1; SMN2 Q16637 2/20 0.98
NR1I2 O75469 1/20 0.98
ABCB11 O95342 1/20 0.98
GC P02774 1/20 0.98
PGR P06401 1/20 0.98
RXRA P19793 1/20 0.98
CHRM3 P20309 1/20 0.98
CNR1 P21554 1/20 0.98
HTR2C P28335 1/20 0.98
MAPK1 P28482 1/20 0.98
SLC6A4 P31645 1/20 0.98
ADRA1A P35348 1/20 0.98
PTGS2 P35354 1/20 0.98
OPRD1 P41143 1/20 0.98
OPRK1 P41145 1/20 0.98

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Calcitriol SCHEMBL2733051 0.99 VDR (1.00) VDRMAPTADORA3SLC6A2AGTR1
Calcitriol SCHEMBL17973736 0.99 VDR (1.00) VDRMAPTADORA3SLC6A2AGTR1
Calcitriol SCHEMBL3488822 0.99 VDR (1.00) VDRMAPTADORA3SLC6A2AGTR1
Calcitriol SCHEMBL23386523 0.99 VDR (1.00) VDRMAPTADORA3SLC6A2AGTR1
Calcitriol SCHEMBL14027727 0.99 VDR (1.00) VDRMAPTADORA3SLC6A2AGTR1
Calcitriol SCHEMBL24066838 0.99 VDR (1.00) VDRMAPTADORA3SLC6A2AGTR1
Calcitriol SCHEMBL2641696 0.99 VDR (1.00) VDRMAPTADORA3SLC6A2AGTR1
Calcitriol SCHEMBL15169024 0.99 VDR (1.00) VDRMAPTADORA3SLC6A2AGTR1
Calcitriol SCHEMBL21055106 0.99 VDR (1.00) VDRMAPTADORA3SLC6A2AGTR1
Calcitriol SCHEMBL13989116 0.99 VDR (1.00) VDRMAPTADORA3SLC6A2AGTR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8853188-B2 Compositions and methods for cancer treatment WOMEN AND INFANTS HOSPITAL OF RI, INC. (US) 2014-10-07 US disclosed
US-20120270839-A1 COMPOSITIONS AND METHODS FOR CANCER TREATMENT WOMEN AND INFANTS HOSPITAL OF RI (US) 2012-10-25 US disclosed
US-20100144671-A1 Compositions and Methods for Cancer Treatment WOMEN AND INFANTS HOSPITAL OF RI, INC. (US) 2010-06-10 US disclosed
WO-2006096555-A1 COMPOSITIONS AND METHODS FOR CANCER TREATMENT WOMEN AND INFANTS HOSPITAL OF RI, INC. (US) 2006-09-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120270839-A1 COMPOSITIONS AND METHODS FOR CANCER TREATMENT CYP24A1, BAX, BAD VDR 4/4885MAPT 3125/4885ADORA3 1798/4885
US-20100144671-A1 Compositions and Methods for Cancer Treatment CYP24A1, BAX, BAD VDR 4/4885MAPT 3125/4885ADORA3 1798/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.